AgeReset Bio

CELL THERAPY

Resetting

the body's *biological clock.*

PLATFORM	INDICATION	ASK
Autologous DPC	Reversal of aging	$420,000

PRE-SEED · 2026

Rejuvenation, borrowed from evolution.

Not a drug.
Not donor cells.
Not Yamanaka factors.
Restoring the body's own young reserve.

DPC are pluripotent cells in a dormant state, derived from the patient's own cells. We activate them, expand them and return them to the body — no donor, no oncogenic risk.

0

interventions in human history have extended the *maximum human lifespan.*

Caloric restriction:
not proven in humans

Senolytics, rapamycin, metformin:
+1–3 years at best

Longevity investment 2020–2026: $50B+
Breakthrough in humans: still none

> *What's needed is an approach that targets the **root causes of aging**, not the symptoms.*

$7B of capital. *The same wall.*

Every approach hits its own ceiling. No one has broken through.

	EXAMPLES	WHY IT FAILS	CAPITAL
Pharmacology	Rapamycin · Metformin · Senolytics	→ Aging runs on many redundant mechanisms — blocking a single target yields no breakthrough	**$2B+**
Allogeneic (donor cells)	MSC therapies	→ Cleared by the immune system within 48 h; the effect comes down to exosomes	**$1B+**
Autologous (own aged cells)	Cell clinics	→ Cells carry the patient's age burden — therapeutic efficacy is limited from the start	**$0.5B+**
Partial reprogramming	Altos Labs · Retro Bio	→ A narrow therapeutic window creates unacceptable oncogenic risk	**$3.5B**

A CLUE FROM BIOLOGY

Hydra don't age. Jellyfish don't age. *Why?*



They keep an active pool of pluripotent cells all their lives and constantly **replace old cells with young ones**. Full cellular repair switches on only in the pluripotent state. Mammals have lost this ability. **We will restore it.**

The DPC platform.
Three tracks — one protocol.

01 · Clear the noise

THERAPEUTIC PLASMAPHERESIS

Remove circulating aging factors from the blood. Reset the systemic environment.

02 · Restore the signal

YOUNG EXOSOMES AND REGULATORY FACTORS

Restore youthful signaling molecules and prepare the cellular niche for renewal.

03 · Renew the source

AUTOLOGOUS DORMANT PLURIPOTENT CELLS

Replace the aging stem-cell pool with the patient's own young pluripotent reserve.

DPC checks every box.

Comparison on key safety and efficacy parameters.

PARAMETER	ALLOGENEIC (MSC)	IPSC	PARTIAL REPROG.	DPC (OUR APPROACH)
Cell source	**Donor**	**Patient**	In situ	**Patient**
Immune rejection	**Yes**	**No**	**No**	**No**
Oncogenic risk	**Low**	**High**	**Moderate**	**Low***
Full epigenetic age reset	**No**	**Yes**	Partial	**Yes***
Autologous	**No**	**Yes**	**Yes**	**Yes**

A confirmed non-oncogenic profile of DPC removes the main barrier for rejuvenation cell therapies.

** Requires experimental validation (stages 2–3).*

Longevity is no longer *a niche market.*

$165B

Invested in cell and regenerative technologies, 2000–2025

~$240B forecast by 2030 · Alliance for Regenerative Medicine

$50B

Longevity and healthspan investment, 2020–2026

Altos · Calico · Retro · PrimeGen · Hevolution / Longevity.Technology

2.1B

People aged 60+ worldwide by 2050 (×3.5 vs 2000)

UN World Population Prospects · WHO

Population 60+, billions

The pool of therapy buyers grows 3.5× within a generation



From hypothesis to PoC in 7 months.

One month to obtain the cells — then all tracks run **in parallel**. Each track's duration is included in the total experiment time.

01 · DPC derivation
Isolation and characterization of the dormant pluripotent cell pool.

02 · Functional validation
Confirmation of trilineage differentiation into all three germ layers.

03 · Safety profile
Long-term follow-up: the longer it runs, the more convincing the absence of tumor risk.

04 · PoC in aged mice
1 month of animal acclimatization; 4–5 months of experiment. Longer follow-up strengthens the result.

7 months and $420K — one decision at the end: go or no-go on Series A.

$420K

Pre-seed round. One ticket. One go/no-go gate at the end of the entire experiment.

If validation succeeds — the foundation for Series A.
If the result is negative — minimal capital exposure, fast.

- **Lab & reagents 55%**
  Cell isolation · characterization
- **Staff (FTE) 30%**
  Senior scientist · operations
- **Equipment 10%**
  Flow cytometry · sequencing
- **Operations 5%**
  Cloud · admin · IP

100+ years of combined experience.
One mission.

Eugene Baranov

CEO

25+ years in stem cell, oncology and aging research. 30+ publications, patents.

Vadim Stepanov

CMO

Clinical lead. Stem cell and plasmapheresis trials, clinic management experience.

Gordana Olbina, Ph.D.

LAB DIRECTOR

Ex-Intrinsic Life Sciences. CLIA/CAP launch, $5M in clinical projects. 20+ publications.

Hui Ma, Ph.D.

SENIOR SCIENTIST

UC San Diego · Salk · Max Planck. Publications in Cell, PNAS, EMBO J. Co-inventor of a lifespan patent.

Three assets. *One ticket.*

Equity round · **$420K** · Pre-seed 2026

01 · EQUITY

10% stake

Direct equity at the pre-seed valuation.

Priority entry into Series A on the current round's terms — no discount, no competition.

02 · DATA

Full PoC package in 7 months

DPC isolation · pluripotency profile · safety verification.

Go/no-go gate — the investor sees the data and decides on Series A based on facts.

03 · POSITION

First check in a new category

Altos Labs raised $3B. Calico, $1B+.

Entry here — $420K. Once the technology is confirmed, this is a founder's position, not a follower's.

*If validation succeeds — you're in from **day one**. If the result is negative — **minimal capital exposure**, fast.*

AgeReset Bio

Our success will take medicine to *the next level of effectiveness.*

DPC removes the fundamental barriers of cell therapy — opening the way to a universal platform for age-related diseases, autoimmune conditions, oncology and systemic tissue regeneration.

Join the work.

AgeReset Bio — a company at the heart of global biotech, San Diego.

Eugene Baranov, CEO · ebaranov@ageresetbio.com · +1 858-334-5698 · San Diego, California · ageresetbio.com